PremiumRatingsAllogene Therapeutics: Strategic Cash Management and ALPHA3 Potential Drive Buy Rating Amid Clinical Delays Allogene Therapeutics price target lowered to $10 from $14 at Truist Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer PremiumThe FlyAllogene downgraded to Market Perform from Outperform at Citizens JMP Allogene Therapeutics Advances Clinical Trials and Extends Cash Runway Allogene Therapeutics reports Q1 EPS (28c), consensus (29c) PremiumRatingsAllogene Therapeutics: Buy Rating Backed by Promising Pipeline Developments and Strong Financial Position Allogene Therapeutics price target lowered to $8 from $9 at H.C. Wainwright Allogene Therapeutics management to meet virtually with Truist